{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012133","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2022-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.430356+00:00","generated_at":"2026-06-24T23:01:38.764428+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relay Therapeutics announces FDA alignment on RLY-4008 accelerated path; 62% response rate in CCA","bullets":["FDA aligned on single-arm trial design for RLY-4008 at 70mg QD to potentially support accelerated approval in FGFRi-naïve FGFR2-fusion CCA.","Interim data: 8 of 13 (62%) FGFRi-naïve FGFR2-fusion CCA patients had confirmed partial responses; all 4 at 70mg QD responded.","Safety manageable: no Grade 4/5 AEs; off-target hyperphosphatemia and diarrhea clinically insignificant.","New breast cancer programs: selective CDK2 inhibitor (clinic Q4 2023/Q1 2024), ERα degrader (candidate 2023), pan-mutant PI3Kα RLY-5836 (clinic 2023).","Cash, cash equivalents and investments expected to fund current operating plan into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012133","json":"https://secwatch.observer/filing/0000950170-22-012133.json","markdown":"https://secwatch.observer/filing/0000950170-22-012133.md","text":"https://secwatch.observer/filing/0000950170-22-012133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022012133/0000950170-22-012133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022012133/rlay-20220627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:01:38.764428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}